Topics

Genexine Inc. Company Profile

07:44 EDT 21st September 2019 | BioPortfolio

Genexine, Inc, listed on KOSDAQ (095700-KQ) since 2009, is a clinical stage biotherapeutics company focused on immuno-oncology,metabolic and autoimmune diseases. Genexine has robust R&D pipelines in clinical and pre-clinical stages based on long-acting Fc fusion technology and therapeutic DNA vaccine technology. In the clinical stage, Genexine has GX-H9 (long-acting human growth hormone, hGH-hyFc) co-developed with Handok for both adult and pediatric GHD, currently in multinational phase II trials. GX-188E therapeutic DNA vaccine for HPV-associated diseases is in Phase II in Europe and Korea for Cervical Intraepithelial Neoplasia II/III and plans to enter into Phase 1b/2a trial in cervical cancer with GX-188E in combination Keytruda (anti- PD-1 therapy) of Merck (also known as MSD) 1H of 2017. Currently Genexine is running over 9 clinical trials from Phase I to Phase IIb in Europe and Asia. In addition to Merck (MSD) collaboration, Genexine has strategic partnerships with leading Asian companies such as Shanghai Fosun Pharma, Tasly Pharma, Kalbe Pharma (largest healthcare Indonesian company), and Korean big Pharma companies such as Handok, Green Cross and Yuhan. Founded in 1999, Genexine has over 150 employees and half of them are scientists with MSc or Ph.D. Genexine is located in Pangyo Techno Valley near Seoul, Korea with a branch office in New York. More information can be found at www.genexine.com


News Articles [10 Associated News Articles listed on BioPortfolio]

Genexine and NIT dose first patient in Hyleukin-7 and Keytruda trials

Biotherapeutics company Genexine and biotech firm NeoImmuneTech (NIT) have dosed the first patient in the combination trial of Hyleukin-7 with...Read More... The post Genexine and NIT dose first patie...

Genexine Hopes To Become 'Asia’s Amgen' After ToolGen Merger

With an ambition to become an Amgen-like global biopharma, South Korea's Genexine decides to merge with local genome editing firm...  

Genexine, ToolGen Merger Collapses Amid Stock Drops, But Collaboration Still Planned

The planned merger between Genexine and ToolGen, which was poised to create a major Korean biotech entity, has collapsed amid...   

SCM, Genexine purchase Argos

KG Bio and Henlius pen antibody agreement; KG Bio gets rights

Shanghai Henlius Biotech Inc. granted PT Kalbe-Genexine Biologics (KG Bio) exclusive rights to develop and sell the anticancer immunotherapy HLX10 in the Asia Pacific territory including the Philippin...

Korean Firms Join Hands To Pick Up Troubled US Cancer Vaccine Firm Argos

Argos Therapeutics lands in the hands of Genexine and SCM Lifescience after the US immunotherapy firm was put up for...   

Genexine and NeoImmuneTech Announce Dosing of First Patient in the Combination Trial of Hyleukin-7™ with Merck’s KEYTRUDA® in Triple-Negative Breast Cancer

Genexine, Inc. (Genexine) and NeoImmuneTech, Inc. (NIT), a T cell-focused therapeutics company, today announced that the first patient has been dosed in a combination regimen tria...

Boehringer Ingelheim, Yuhan sign £689m NASH license deal

The fusion protein, which is being developed for NASH, utilises the HyFc technology of Genexine. It has been developed in-house by South Korean pharma company. The fusion protein The post Boehringer ...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [5 Associated Companies listed on BioPortfolio]

Genexine, Inc.

Genexine, Inc., listed on KOSDAQ (095700) since 2009, is a leading biotherapeutics company focused on immuno-oncology and orphan disease. Genexine has robust pipelines in clinical...

Genexine Inc.

Genexine, Inc, listed on KOSDAQ (095700-KQ) since 2009, is a clinical stage biotherapeutics company focused on immuno-oncology,metabolic and autoimmune diseases. Genexine has robu...

NeoImmuneTech, Inc.

NeoImmuneTech (NIT), a Genexine related company founded in 2014, is focused on leading the development efforts for its flagship immunotherapy product, Hyleukin-7, in the U.S. and ...

NeoImmuneTech

NeoImmuneTech, a Genexine related company founded in 2014, is focused on leading the development efforts for its flagship immunotherapy product, HyLeukin-7, in the US and EU. Base...

Ichor Medical Systems

Ichor Medical Systems’ TriGrid™ Delivery System is the first integrated and fully automated system for electroporation-mediated DNA administration in humans. Ichor, a pr...

More Information about "Genexine Inc." on BioPortfolio

We have published hundreds of Genexine Inc. news stories on BioPortfolio along with dozens of Genexine Inc. Clinical Trials and PubMed Articles about Genexine Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Genexine Inc. Companies in our database. You can also find out about relevant Genexine Inc. Drugs and Medications on this site too.

Quick Search

Relevant Topics

Biotechnology Products
BioPortfolio lists over 550 biotechnology products - please open http://www.bioportfolio.com/channels?category_id=5 Direct topic pages: Actos Advair Biopharmaceuticals Biosimilars Biotherapeutics GMO Crops Lipitor ...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Autoimmune Disorders
Autoimmune disorders are conditions that occurs when the immune system mistakenly attacks and destroys healthy body tissue. There are more than 80 different types of autoimmune disorders. Normally the immune system's white blood cells help protect ...


Corporate Database Quicklinks



Searches Linking to this Company Record